DC-CIK自体细胞免疫疗法在非小细胞型肺癌治疗中的研究进展  

Breakthroughs in dendritic cell-cytokine-induced killer therapy for non-small cell lung cancer

作　　者：刘若水 谭浩 王跃[2] Liu Ruoshui;Tan Hao;Wang Yue(Shanghai Jiao Tong University School of Medicine,Shanghai 200021;Department of Thoracic Surgery,China-Japan Union Hospital of Jilin University,Changchun 130033)

机构地区：[1]上海交通大学医学院,上海200021 [2]吉林大学中日联谊医院胸外科,长春130033

出　　处：《国际老年医学杂志》2025年第2期216-220,共5页International Journal of Geriatrics

基　　金：吉林省科技厅资助项目(20200603006SF);陈孝平基金会资助项目(CXPJJH122002-041)。

摘　　要：随着免疫疗法在肿瘤治疗领域的广泛应用,DC-CIK自体细胞免疫疗法作为一种新兴的非小细胞肺癌(NSCLC)免疫治疗方法备受关注。该疗法能够激活患者自身免疫系统,促进T淋巴细胞的增殖和活化,从而增强抗肿瘤免疫反应,显著延长患者生存期,改善患者生活质量,且安全性较好。本文对DC-CIK自体细胞免疫疗法的发展历程、在NSCLC中的机制及现状作一综述,为NSCLC的免疫治疗提供帮助。With the increasing adoption of immunotherapy in oncology,dendritic cell-cytokine-induced killer(DC-CIK)autologous cell immunotherapy has emerged as a promising strategy for the treatment of non-small cell lung cancer(NSCLC).This approach leverages the patient s immune system by stimulating the proliferation and activation of T lymphocytes,thereby enhancing the anti-tumor immune responses.Clinical trials have demonstrated notable improvements in both immunological outcomes and clinical efficacy,with DC-CIK therapy contributing to prolonged survival and improved quality of life for NSCLC,while maintaining an acceptable safety profile.Despite these advancements,challenges remain,necessitating further comprehensive clinical studies to establish the long-term efficacy and survival benefits of DC-CIK therapy.

关 键 词：DC-CIK疗法 非小细胞肺癌 自体细胞免疫疗法 肿瘤生物治疗 

分 类 号：R73[医药卫生—肿瘤]